Last reviewed · How we verify
Investigator choice of standard therapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Investigator choice of standard therapy (Investigator choice of standard therapy) — iOnctura.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Investigator choice of standard therapy TARGET | Investigator choice of standard therapy | iOnctura | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Investigator choice of standard therapy CI watch — RSS
- Investigator choice of standard therapy CI watch — Atom
- Investigator choice of standard therapy CI watch — JSON
- Investigator choice of standard therapy alone — RSS
Cite this brief
Drug Landscape (2026). Investigator choice of standard therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/investigator-choice-of-standard-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab